secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2025-07-08T23:59:59+00:00
Accession:  0001104659-25-066451
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CFO Gordon Dunn to depart Quoin Pharmaceuticals; will continue until successor named
--------------------------------------------------------------------------------

- Mutual separation agreed on July 3, 2025; CFO Gordon Dunn to leave later this year.
- Mr. Dunn will continue in his role until his successor is appointed.
- Separation agreement anticipated; will be filed as an exhibit to a future Form 8-K or periodic report.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925066451/0001104659-25-066451-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925066451/tm2520110d_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-066451

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer